New drug cocktail shows promise for cervical cancer before surgery
NCT ID NCT07055399
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with chemotherapy before surgery can help shrink tumors in people with locally advanced cervical cancer. The study will enroll 43 participants and measure how many have no cancer cells left at the time of surgery. It is an early-stage study, so results are not yet proven.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab and tuvonralimab (a dual PD-1/CTLA-4 blocker) plus cisplatin and nab-paclitaxel chemotherapy
What this could lead to
If successful, this approach could offer a more effective way to shrink tumors before surgery, potentially improving long-term outcomes for patients with locally advanced cervical cancer.
What could go wrong
This is a small, early-phase trial (43 participants) with no control group, so results may not be definitive. The drug combination may cause significant side effects, and not all patients may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact